Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women

Journal of Infectious Diseases

Volumn 210, Issue 12, 2014, Pages 1938-1945

  Natureeba, Paul ^a   Ades, Veronica ^b   Luwedde, Flavia ^a   Mwesigwa, Julia ^a   Plenty, Albert ^c   Okong, Pius ^a   Charlebois, Edwin D ^c   Clark, Tamara D ^c   Nzarubara, Bridget ^a   Havlir, Diane V ^c   Achan, Jane ^a   Kamya, Moses R ^a   Cohan, Deborah ^d   Dorsey, Grant ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b NEW YORK UNIVERSITY   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Efavirenz; HIV; Lopinavir ritonavir; Malaria; Pregnancy

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; BENZOXAZINE DERIVATIVE; COTRIMOXAZOLE; LOPINAVIR; RITONAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA CONTROL; PLACENTA MALARIA; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING; ADOLESCENT; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MALARIA; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LOPINAVIR; MALARIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RITONAVIR; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; YOUNG ADULT;

EID: 84920261882     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu346     Document Type: Article

References (28)

1. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93-104.
2. Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 2011;11:541-56.
3. Ned RM, Moore JM, Chaisavaneeyakorn S, Udhayakumar V. Modulation of immune responses during HIV-malaria co-infection in pregnancy. Trends Parasitol 2005;21:284-91.
4. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004;71:41-54.
5. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendatinos for a public health approach. http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf. Accessed May 2014.
6. Iriemenam NC, Shah M, Gatei W, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malaria J 2012;11:134.
7. Ranson H, N'Guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol 2011;27:91-8.
8. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland: WHO, 2013.
9. Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrobial Agents Chemother 2011;55:5073-7.
10. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005;49:2983-5.
11. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004;190:1998-2000.
12. Parikh S, Liu J, Sijwali P, Gut J, Goldberg DE, Rosenthal PJ. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob Agents Chemother 2006;50:2207-9.
13. Achan J, Kakuru A, Ikilezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 2012;367:2110-8.
14. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006;75:219-25.
15. Uganda Ministry of Health. Uganda clinical guidelines. http://www.health.go.ug/docs/ucg-2010.pdf. Accessed May 2014.
16. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol 1993;58:283-92.
17. Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, Molyneux ME. Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. Am J Trop Med Hyg 2003;68:115-9.
18. Cohan D, Natureeba P, Plenty A, et al. Efficacy and safety of LPV/r versus EFV in HIV+ pregnant and breast-feeding Ugandan women. Presented at: Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2014.
19. Newman PM, Wanzira H, Tumwine G, et al. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malaria J 2009;8:254.
20. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother 2006;50:639-48.
21. Nathoo S, Serghides L, Kain KC. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparumparasitised erythrocytes. Lancet 2003;362:1039-41.
22. Skinner-Adams TS, Butterworth AS, Porter KA, et al. The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One 2012;7:e34399.
23. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of cotrimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011;342:d1617.
24. German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009;51:424-9.
25. McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006;62:1021-31.
26. Tarning J, McGready R, Lindegardh N, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemetherlumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009;53:3837-46.
27. Fried M, Muehlenbachs A, Duffy PE. Diagnosing malaria in pregnancy: an update. Expert Rev Anti Infect Ther 2012;10:1177-87.
28. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 2011;203:464-72.